Suzetrigine

DB18927ApprovedInvestigationalSmall moleculeSodium Channel Blockers

Suzetrigine is a sodium channel blocker used to treat moderate to severe acute pain in adults. Suzetrigine is a NaV1.8 voltage-gated sodium channel blocker with analgesic properties NaV1.8 is abundantly expressed in peripheral sensory nerves to play a role in pain signal transmission, making it a desirable therapeutic target for treatment...

Mechanism: Suzetrigine is a selective blocker of the NaV1.8 voltage-gated sodium channel, which is expressed in peripheral nociceptive neurons, including dorsal root ganglion neurons, to play a role in transmitting nociceptive signals. By blocking the sodium channels, suzetrigine stops the transmission of pain signals to the spinal cord and brain. M6-SUZ, the primary active metabolite, is 3.7 times less potent than suzetrigine as an inhibitor of NaV1.8.
Curator reviewed · 4 references
Primary indication: Suzetrigine is indicated for the treatment of moderate to severe acute pain in adults.Curator reviewed · 2 structured indications
Formula / weight: C₂₁H₂₀F₅N₃O₄ · 473.4 g/mol (avg)
First approval: United States, 2025
Also known as: 2-Pyridinecarboxamide, 4-[[[(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)tetrahydro-4,5-dimethyl-5-(trifluoromethyl)-2-furanyl]carbonyl]amino]- · 4-[(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5- dimethyl-5-(trifluoromethyl)oxolane-2- carboxamido]pyridine-2-carboxamide · 4-[(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)oxolane-2-amido]pyridine2-carboxamide · 4-[[[(2R,3S,4S,5R)-3-(3,4-Difluoro-2-methoxyphenyl)tetrahydro-4,5-dimethyl-5-(trifluoromethyl)-2-furanyl]carbonyl]amino]-2-pyridinecarboxamide
Code names: CS-0641183 · HY-148800 · VX-548
Brand names: Journavx